Introduction Immune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring
molecular alterations remains poorly elucidated. This study was undertaken to determine ICI …

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small
cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-…

Background There is no recommended therapy for malignant pleural mesothelioma that has
progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control …

Anti-PD1 immunotherapy has emerged as a gold-standard treatment for first- or second-line
treatment of stage IV NSCLC, with response rates ranging from 10 to 60%. Strategies to …

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …

Immune checkpoint inhibitors, notably antibodies targeting programmed death–1 (PD-1)
and programmed death ligand–1 (PD-L1), have modified the management of patients with …

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

Objective Immune checkpoint inhibitors ( ICI s) for cancer therapy frequently induce immune‐related
adverse effects ( IRAE s). Therefore, most patients with preexisting autoimmune …

Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …

Introduction Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …